SCHEMBL19414295

SCHEMBL19414295

COc1ccc(-c2n[nH]c3ncnc(N)c23)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 16/20 0.47
▸ ABL1 P00519 13/20 0.47
▸ PIK3CD O00329 11/20 0.47
▸ EGFR P00533 11/20 0.47
▸ HCK P08631 11/20 0.47
▸ PIK3CA P42336 11/20 0.47
▸ PIK3CB P42338 11/20 0.47
▸ MTOR P42345 11/20 0.47
▸ PIK3CG P48736 11/20 0.47
▸ EPHB4 P54760 11/20 0.47
▸ PRKDC P78527 11/20 0.47
▸ KDR P35968 10/20 0.47
▸ PI4KB Q9UBF8 10/20 0.47
▸ ADORA2A P29274 1/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ KMO O15229 1/20 0.43
▸ LIMK1 P53667 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11214 0.90 DYRK1A (0.48) SRCABL1PIK3CDEGFRHCK
SCHEMBL149180 0.88 PIK3CD (0.55) SRCABL1PIK3CDEGFRHCK
SCHEMBL20093481 0.87 KMO (0.46) SRCABL1PIK3CDEGFRHCK
SCHEMBL11306 0.85 SRC (0.47) SRCABL1PIK3CDEGFRHCK
SCHEMBL17626717 0.83 PIK3CD (0.47) PIK3CDEGFRPIK3CAPIK3CBPIK3CG
SCHEMBL16665685 0.83 PIK3CD (0.67) SRCABL1PIK3CDEGFRHCK
SCHEMBL10811 0.82 SRC (0.57) SRCABL1PIK3CDEGFRHCK
SCHEMBL20093445 0.82 EGFR (0.50) SRCABL1PIK3CDEGFRHCK
SCHEMBL13293328 0.81 ERBB2 (0.56) EGFR
SCHEMBL17365228 0.81 PDGFRB (0.46) SRCABL1PIK3CDEGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2021-06-01 — — US disclosed
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-09-19 — — US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases MAP4K2, MAP3K20, MAP3K1 SRC 85/4885ABL1 106/4885PIK3CD 288/4885
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885ABL1 334/4885PIK3CD 47/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A SRC 110/4885ABL1 258/4885PIK3CD 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback